Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
BackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the L...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00624/full |
id |
doaj-0fe60b47876e442bbf49c0c4a06d41cf |
---|---|
record_format |
Article |
spelling |
doaj-0fe60b47876e442bbf49c0c4a06d41cf2020-11-25T03:32:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-05-011110.3389/fphar.2020.00624512495Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines InitiativeMuh. Akbar Bahar0Muh. Akbar Bahar1Jens H. J. Bos2Sander D. Borgsteede3Aafje Dotinga4Rolinde A. Alingh5Bob Wilffert6Bob Wilffert7Eelko Hak8Unit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsFaculty of Pharmacy, Hasanuddin University, Makassar, IndonesiaUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsDepartment of Clinical Decision Support, Health Base Foundation, Utrecht, NetherlandsLifelines Cohort Study, Lifelines Databeheer B.V., Roden, NetherlandsLifelines Cohort Study, Lifelines Databeheer B.V., Roden, NetherlandsUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, NetherlandsUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, NetherlandsBackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.MethodsAs part of the University of Groningen PharmLines Initiative, data were collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires of Lifelines participants and linked information from the pharmacy database IADB.nl. CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e. chronically used medication (CM) or occasionally used medication (OM). This resulted in the combination of two chronically used drugs (CM-CM), chronically and occasionally used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the agreement level, cohen’s kappa statistics and test characteristics were used. Results were stratified by time window, gender, and age.ResultsAmong 80,837 medicine users in the Lifelines, about 1–2 per hundred participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall, the overlapping time window of three months produced the highest mean kappa values between the databases i.e. 0.545 (95% CI:0.544–0.545), 0.512 (95% CI:0.511–0.512), and 0.374 (95% CI:0.373–0.375), respectively. CM-CM had a better level of agreement (good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The influence of gender on concordance values was different for different CYPs. Among older persons, agreement levels were higher than for the younger population.ConclusionsCYP2D6/2C19/2C9-mediated potential DDIs were frequent and concordance of data varied by time window, type of combination, sex and age. Subsequent studies should rather use a combination of self-reported and pharmacy database information.https://www.frontiersin.org/article/10.3389/fphar.2020.00624/fullCYP2D6CYP2C19CYP2C9drug-drug-interactionLifelinesIADB.nl |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Muh. Akbar Bahar Muh. Akbar Bahar Jens H. J. Bos Sander D. Borgsteede Aafje Dotinga Rolinde A. Alingh Bob Wilffert Bob Wilffert Eelko Hak |
spellingShingle |
Muh. Akbar Bahar Muh. Akbar Bahar Jens H. J. Bos Sander D. Borgsteede Aafje Dotinga Rolinde A. Alingh Bob Wilffert Bob Wilffert Eelko Hak Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative Frontiers in Pharmacology CYP2D6 CYP2C19 CYP2C9 drug-drug-interaction Lifelines IADB.nl |
author_facet |
Muh. Akbar Bahar Muh. Akbar Bahar Jens H. J. Bos Sander D. Borgsteede Aafje Dotinga Rolinde A. Alingh Bob Wilffert Bob Wilffert Eelko Hak |
author_sort |
Muh. Akbar Bahar |
title |
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative |
title_short |
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative |
title_full |
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative |
title_fullStr |
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative |
title_full_unstemmed |
Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative |
title_sort |
prevalence and accuracy of information on cyp2d6, cyp2c19, and cyp2c9 related substrate and inhibitor co-prescriptions in the general population: a cross‐sectional descriptive study as part of the pharmlines initiative |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-05-01 |
description |
BackgroundDrug-drug interaction (DDI) is one of the main contributors to adverse drug reactions and therefore, it is important to study its frequency in the population. We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.MethodsAs part of the University of Groningen PharmLines Initiative, data were collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires of Lifelines participants and linked information from the pharmacy database IADB.nl. CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e. chronically used medication (CM) or occasionally used medication (OM). This resulted in the combination of two chronically used drugs (CM-CM), chronically and occasionally used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the agreement level, cohen’s kappa statistics and test characteristics were used. Results were stratified by time window, gender, and age.ResultsAmong 80,837 medicine users in the Lifelines, about 1–2 per hundred participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall, the overlapping time window of three months produced the highest mean kappa values between the databases i.e. 0.545 (95% CI:0.544–0.545), 0.512 (95% CI:0.511–0.512), and 0.374 (95% CI:0.373–0.375), respectively. CM-CM had a better level of agreement (good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The influence of gender on concordance values was different for different CYPs. Among older persons, agreement levels were higher than for the younger population.ConclusionsCYP2D6/2C19/2C9-mediated potential DDIs were frequent and concordance of data varied by time window, type of combination, sex and age. Subsequent studies should rather use a combination of self-reported and pharmacy database information. |
topic |
CYP2D6 CYP2C19 CYP2C9 drug-drug-interaction Lifelines IADB.nl |
url |
https://www.frontiersin.org/article/10.3389/fphar.2020.00624/full |
work_keys_str_mv |
AT muhakbarbahar prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT muhakbarbahar prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT jenshjbos prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT sanderdborgsteede prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT aafjedotinga prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT rolindeaalingh prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT bobwilffert prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT bobwilffert prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative AT eelkohak prevalenceandaccuracyofinformationoncyp2d6cyp2c19andcyp2c9relatedsubstrateandinhibitorcoprescriptionsinthegeneralpopulationacrosssectionaldescriptivestudyaspartofthepharmlinesinitiative |
_version_ |
1724569689125814272 |